首页 / 产品 / 蛋白 / 细胞因子、趋化因子与生长因子
| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | CD30L |
| Uniprot No | P32971 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 63-234aa |
| 氨基酸序列 | QRTDSIPNSPDNVPLKGGNCSEDLLCILKRAPFKKSWAYLQVAKHLNKTK LSWNKDGILHGVRYQDGNLVIQFPGLYFIICQLQFLVQCPNNSVDLKLEL LINKHIKKQALVTVCESGMQTKHVYQNLSQFLLDYLQVNTTISVNVDTFQ YIDTSTFPLENVLSIFLYSNSD |
| 预测分子量 | 22 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于CD30L重组蛋白的示例参考文献(内容为模拟概括，建议通过学术数据库获取真实文献)：
---
1. **标题**: *Expression and functional characterization of recombinant human CD30 ligand in mammalian cells*
**作者**: Smith A, et al.
**摘要**: 研究通过哺乳动物表达系统成功表达并纯化功能性CD30L重组蛋白，验证其与CD30受体的特异性结合能力，并证明其可激活NF-κB信号通路，为后续免疫治疗研究奠定基础。
---
2. **标题**: *CD30 ligand-dependent cell death in T-cell lymphoma: Role of recombinant CD30L in apoptosis induction*
**作者**: Lee B, et al.
**摘要**: 探讨CD30L重组蛋白在体外诱导CD30阳性淋巴瘤细胞凋亡的作用，发现其通过激活Caspase通路和抑制生存信号，提示其潜在抗肿瘤应用价值。
---
3. **标题**: *Structural insights into CD30L trimerization and receptor interaction by engineered recombinant variants*
**作者**: Chen X, et al.
**摘要**: 通过基因工程改造CD30L重组蛋白，解析其三聚体结构及与CD30受体结合的关键表位，为优化靶向治疗分子提供结构生物学依据。
---
4. **标题**: *Recombinant CD30L fusion protein enhances antitumor immunity in murine models*
**作者**: Wang Y, et al.
**摘要**: 构建CD30L-抗体融合蛋白，在小鼠模型中验证其通过激活T细胞和抑制调节性T细胞(Treg)功能，显著增强抗肿瘤免疫应答的效果。
---
**注意**：以上为模拟摘要，实际文献需通过PubMed、Web of Science等平台检索关键词(如“recombinant CD30L”、“CD30 ligand protein”)。
CD30 ligand (CD30L), also known as CD153. is a transmembrane protein belonging to the tumor necrosis factor (TNF) superfamily. It binds to its receptor CD30. a cell surface antigen predominantly expressed on activated T and B lymphocytes, as well as malignant cells in certain lymphomas, including Hodgkin’s lymphoma and anaplastic large-cell lymphoma. The CD30L-CD30 interaction plays a critical role in modulating immune responses, particularly in T-cell-mediated immunity, inflammation, and cellular communication between immune cells. Dysregulation of this pathway has been implicated in autoimmune diseases and cancer progression, making it a therapeutic target of interest.
Recombinant CD30L proteins are engineered versions of the native protein, typically produced in mammalian or bacterial expression systems. These proteins often lack the transmembrane domain to create soluble forms (sCD30L) while retaining receptor-binding activity. They may include tags (e.g., Fc fusion or His-tag) to enhance stability and facilitate purification. Structurally, CD30L forms homotrimers, mimicking the natural ligand-receptor engagement required for signaling.
In research, recombinant CD30L is widely used to study CD30/CD30L signaling mechanisms, immune cell activation, and apoptosis regulation. It serves as a tool for in vitro assays to investigate lymphoma biology or evaluate therapeutic agents targeting this axis. Clinically, CD30-directed therapies like antibody-drug conjugates (e.g., Brentuximab vedotin) leverage the CD30-CD30L pathway for targeted cancer treatment. Recent studies also explore recombinant CD30L in immunotherapies, either as agonists to modulate immune responses or as components of bispecific molecules for precision targeting. However, its dual role in promoting both pro-inflammatory and immunosuppressive effects requires careful therapeutic application.
×
